Jeffrey S. Ramsay

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.75 billion aggregate principal amount of its 0.750% senior notes due 2023 and (ii) $1 billion…

Davis Polk advised the underwriters on an SEC-registered offering by BankUnited, Inc. of $300 million aggregate principal amount of 5.125% subordinated notes due 2030.BankUnited, Inc…

Davis Polk advised the representatives of the several underwriters, in connection with the $1.925 billion initial public offering of 77,000,000 shares of Class A common stock of Warner…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $1.0 billion aggregate principal amount of its 3.875% senior notes due 2031. The notes are guaranteed by…

Davis Polk advised the underwriters in connection with the offering of $1.75 billion aggregate principal amount of 1.050% bonds due May 21, 2027 issued by the Province of Ontario. The Davis…

Davis Polk advised the underwriters in connection with the offering of $2.25 billion aggregate principal amount of 1.000% bonds due May 20, 2025, issued by the Province of Alberta. The…

Davis Polk advised the initial purchasers in connection with a concurrent Rule 144A/Regulation S offering by NCLC of $675 million aggregate principal amount of its 12.250% senior…

Davis Polk advised the underwriters in connection with an SEC-registered offering by Norwegian Cruise Line Holdings Ltd. (“NCLH”) of 41,818,181 of its ordinary shares (including 5,454…